NEW BRUNSWICK, N.J. (AP) – Johnson & Johnson is seeking U.S. approval for a third use for its anticlotting pill, Xarelto.

The company’s Janssen Research & Development unit has asked the Food and Drug Administration to approve the clot-preventing drug for patients with acute coronary syndrome.

Xarelto was approved for use in patients with atrial fibrillation. It was first approved in July 2011, for preventing dangerous blood clots in patients undergoing hip or knee replacement surgery.

The Associated Press